Economic evaluation in cardiology

Europace

Volumn 13, Issue SUPPL. 2, 2011, Pages

  Maniadakis, Nikos ^a   Vardas, Panos ^b   Mantovani, Lorenzo G ^c   Fattore, Giovanni ^d   Boriani, Giuseppe ^e  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d BOCCONI UNIVERSITY   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Budget; Cost effectiveness; Health economics; Healthcare; Resources

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH SERVICE; PRIORITY JOURNAL; QUALITY OF LIFE;

CARDIOLOGY; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; EUROPE; HEALTH CARE COSTS; HEALTH CARE RATIONING; HUMANS; MODELS, ECONOMIC; RESOURCE ALLOCATION;

EID: 79955600597     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur088     Document Type: Article

References (20)

1. Black WC. The cost-effectiveness plane: a graphic representation of cost-effectiveness. Med Decis Making 1990;10:212-5.
2. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
3. Johannesson M. Theory and Methods of Economic Evaluation in Health Care. Dor-drecht: Kluwer; 1996.
4. Sloan F (ed). Valuing Health Care. New York: Cambridge University Press; 1995.
5. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford Medical Publications, Oxford University Press; 1997.
6. Bowling A. Measuring Health: A Review of Quality of Life Measurement Scales. Buckingham: Open University Press; 1997.
7. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;1:76-9.
8. Buxton MJ, Drummond MF, van Hout BA, Prince RL, Sheldon TA, Szucs T et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6: 217-27. (Pubitemid 27296586)
9. O'Brien BJ. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? Med Care 1996;34:DS99-108.
10. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996;5:1-11.
11. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.
12. Bala MV, Mauskopf JA, Wood LL. Willingness to pay as a measure of health benefits. Pharmacoeconomics 1999;15:9-18. (Pubitemid 29039608)
13. Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 1996;5:13-23. (Pubitemid 126478051)
14. Briggs AH, Sculpher MJ. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ 1995;4:355-71.
15. Willan A, O'Brien B. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ 1999;8:203-11. (Pubitemid 29219085)
16. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: issues in the decisions and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994;32:150-63.
17. Van Hout BA, Gordon GS, Rutten FF. Costs, effects and C/E ratios along side a clinical trial. Health Econ 1994;3:309-19.
18. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomised trial. Stat Med 1996;15:1447-58. (Pubitemid 26242553)
19. Karlsson G, Johannesson J. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996;9:113-20. (Pubitemid 26029974)
20. Trueman D, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001;9:609-21. (Pubitemid 32531836)